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AbstrAct
Brain metastasis is a major cause of morbidity and mortality in patients with 
breast cancer. Our previous studies indicated that Stat3 plays an important role in 
brain metastasis. Here, we present evidence that Stat3 functions at the level of the 
microenvironment of brain metastases. Stat3 controlled constitutive and inducible 
VEGFR2 expression in tumor-associated brain endothelial cells. Furthermore, inhibition 
of Stat3 by WP1066 decreased the incidence of brain metastases and increased 
survival in a preclinical model of breast cancer brain metastasis. WP1066 inhibited 
Stat3 activation in tumor-associated endothelial cells, reducing their infiltration and 
angiogenesis. WP1066 also inhibited breast cancer cell invasion. Our results indicate 
that WP1066 can inhibit tumor angiogenesis and brain metastasis mediated by Stat3 
in endothelial and tumor cells.
INtrODUctION
The major cause of death from breast cancer is 
metastases that are resistant to conventional therapies [1]. 
Brain metastasis occurs in about 20% of patients with 
breast cancer and is a major cause of death in patients 
with breast cancer [2]. The prognosis of patients with brain 
metastasis is poor [3-5], with a median survival of 4 to 
6 months, because brain metastases are largely refractory 
to current treatments, including surgery, radiation 
therapy, and chemotherapy. Thus, targeted treatment and 
prevention strategies for brain metastasis are needed to 
improve the survival rate of breast cancer patients.
The formation of brain metastases is determined 
by both tumor cell properties and host factors. Tumor 
cells may release vascular endothelial growth factor 
(VEGF; also known as vascular permeability factor), 
inducing neovascularization in brain metastases [6]. 
Indeed, the progressive growth of brain metastases is 
dependent on expression of VEGF. VEGF activates 
signaling in endothelial cells after binding receptors on 
the cell surface, including VEGF receptor 2 (VEGFR2) 
(KDR/Flk-1). VEGFR2 signaling activates a variety of 
downstream signaling pathways in endothelial cells, 
including the Stat3, PI3K, and MEK-ERK pathways [7-
9], and is responsible for many of the characteristic effects 
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of VEGF on endothelial cells, including cell proliferation, 
survival, migration, and increased vascular permeability 
[10-12]. Moreover, VEGF induces expression of its 
receptors, including VEGFR2 [13, 14], but its molecular 
mechanisms are not fully understood. In the present study, 
we found Stat3 is a direct transcription factor for VEGFR2 
and increases its expression. 
Stat3 is a member of the JAK-STAT (Janus 
kinase-signal transducer and activator of transcription) 
signaling pathway [15, 16]. In breast cancer cells, both 
genetic and epigenetic alterations have been shown to 
activate Stat3, including alterations in Her2/Neu, EGFR, 
BRCA1, and estrogen receptor [17, 18]. Overexpression 
of constitutively activated Stat3 in immortalized breast 
cells induced tumor formation [19]. Stat3 has also been 
linked with cellular proliferation, promotion of apoptosis, 
invasion, angiogenesis, and evasion of host immune 
responses [20-25]. Furthermore, Stat3 activation has been 
implicated as an important driver of brain metastasis in 
breast cancer, although the mechanisms are not fully 
understood [26, 27]. 
In the current study, we sought to determine the 
role of Stat3 in the interaction between endothelial cells 
and tumor cells in breast cancer brain metastasis. We 
tested the effect of a Stat3 inhibitor, WP1066 [29-31], 
on breast cancer brain metastasis in a preclinical mouse 
model. WP1066 has been shown to effectively block 
JAK2 and Stat3 activation in multiple tumor cell types, 
including glioma cell lines [29, 30]. We also explored 
the mechanisms underlying the inhibitory effects of 
WP1066 on metastasis of breast cancer to the brain. We 
demonstrate that WP1066 reduced the incidence of brain 
metastasis and significantly extended the overall survival 
of metastasis-bearing mice. We also show a unique role 
of Stat3 activation via VEGFR2 in orchestrating the 
interaction between endothelial and brain tumor cells and 
promoting breast cancer brain metastasis.
rEsULts
stat3 activation correlated directly with the brain 
metastatic potential of breast cancer cells
We first examined Stat3 activity in MDA-MB-231 
and BT-474 cell lines and in brain metastatic cell lines 
MDA-MB-231BR and BT-474BR. Stat3 activity is 
significantly higher in MDA-MB-231BR and BT-474BR 
cells than in their wild-type counterparts (Fig. 1A), 
indicating that Stat3 was constitutively activated at higher 
levels in brain metastatic breast cancer cells.
Next, we analyzed 90 breast invasive ductal 
carcinoma (IDC) and 89 breast cancer brain metastasis 
specimens using immunohistochemistry for nuclear 
staining of pStat3, the activated form of Stat3. 5.5% of the 
IDC specimens exhibited strong positive, 25.6% moderate 
positive, and 68.9% weak to negative staining for pStat3 
(Fig. 1B and Supplementary Fig. S1). In contrast, 30.3% 
of the brain metastasis specimens exhibited strong 
positive, 46.1% moderate positive, and 23.6% weak to 
negative staining for pStat3. When the data regarding 
strong positive and moderate positive staining were 
analyzed using χ2 test, significantly higher levels of pStat3 
were evident in breast cancer brain metastases than in IDC 
specimens (Fig. 1B; P < 0.001).
WP1066 inhibited stat3 activation in breast 
cancer brain metastatic cells
On the basis of the above findings, we hypothesized 
that treatment with WP1066, a Stat3 inhibitor [29], would 
inhibit brain metastasis by reducing Stat3 activation. 
MDA-MB-231BR and BT-474BR cells were treated with 
1 µM WP1066 for 1 to 24 hours and then examined for 
levels of pStat3. WP1066 substantially decreased pStat3 
level in both cell lines in a time-dependent manner (Fig. 
1C; Supplementary Fig. S2).
brain permeability of WP1066
To determine the brain permeability of WP1066, 
WP1066 (40 mg/kg) was injected intraperitoneally into 
nude mice every other day until three doses had been 
given. After the third dose, the brains were harvested from 
mice, and the plasma and brain concentrations of WP1066 
were measured by LC/MS/MS. WP1066 distribution into 
the brain was more favorable than WP1066 distribution 
into plasma. The concentration of WP1066 in brain tissue 
was 1.06 µM to 1.81 µM (mean 1.50 µM) (Fig. 1D). In 
contrast, the concentration of WP1066 in plasma was 0.10 
µM to 0.027 µM (mean 0.018 µM) (Fig. 1D). Moreover, 
the mean brain/plasma ratio of WP1066 was 92.8 (Fig. 
1D), indicating that brain concentrations of WP1066 were 
more than 90 times plasma concentrations. These data 
indicated a potentially high distribution of WP1066 into 
brain tissue, suggesting activity of WP1066 against brain 
metastases.
WP1066 inhibited brain metastases of breast 
cancer cells in nude mice
We used the well-established brain metastases model 
of MDA-MB-231BR cells to test the effect of WP1066 
on brain metastases [28]. WP1066 treatment (40 mg/kg) 
began on day 3 (early treatment) or 9 (late treatment) after 
tumor cell injection and continued every other day until 
six doses had been given (Supplementary Fig. 1C). Thirty 
days after tumor cell injection, the brains were harvested 
from mice of each group, and the numbers of metastases 
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Figure 1: stat3 activation in breast cancer brain metastases and WP1066 inhibited brain metastasis. (A) pStat3, Stat3, 
and β-actin protein expression levels in MDA-MB-231 and BT-474 cells. (B) Expression levels of pStat3 in 90 IDC and 89 breast cancer 
brain metastasis specimens. ***, P<0.001. (C) MDA-MB-231BR cells and BT-474BR cells were treated with 1 μM WP1066 (wp) for 
the indicated times, and whole-cell lysates were subjected to western blotting for pStat3 (Tyr705), Stat3 and β-actin. (D) Concentration 
of WP1066 in mouse brain tissue and plasma after WP1066 treatment for 72 hours. (E) The effect of WP1066 on the brain metastases of 
MDA-MB231-BR cell in vivo. 5×105 MDA-M-B231-BR cells were injected into the Left ventricle of the heart of nude mice. Results were 
shown for one representative experiment of two. **, P<0.01, ***, P<0.001. (F) HE-stained sections of brain metastases of MDA-MB-
231BR cells in mice. (G) Survival of mice injected with MDA-MB-231BR cells and given later WP1066 treatment. Data are presented from 
the day of injection to day 100. Survival of mice was evaluated by Kaplan-Meier analysis. ***, P<0.001. 
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were determined. Early administration of WP1066 
reduced the number of large metastases by 68.18%, and 
reduced the number of micrometastases by 57.59% (Fig. 
1E). Late administration of WP1066 reduced the number 
of large metastases by 63.63%, and reduced the number of 
micrometastases by 55.36%. 
We also determined the effect of WP1066 on 
survival of mice bearing brain metastases over a 100-day 
period. As shown in Fig. 1F and G, MDA-MB-231BR 
cells produced brain metastases in all of the injected mice, 
and the mice became moribund around 35 days after 
cell injection. In contrast, early treatment with WP1066 
significantly increased the survival of the mice injected 
with MDA-MB-231BR cells (P <0.001). These results 
showed that WP1066 treatment suppressed breast cancer 
cell brain metastasis and increased survival duration in a 
mouse model of brain metastasis.
Effect of WP1066 on survival and proliferation of 
brain metastatic cells
To study the mechanism of inhibition of brain 
metastases by WP1066, we first tested the effect of 
WP1066 on viability of MDA-MB-231BR cells. WP1066 
substantially reduced their survival in a dose-dependent 
manner (Fig. 2A). However, WP1066 inhibited the 
viability of the cells only at concentrations of 3 µM and 
above; WP1066 had no effect at concentrations under 2 
µM (Fig. 2A). Also, WP1066 inhibited the viability of BT-
474BR cells only at concentrations of 2 µM and above 
(Fig. 2A).
Since the concentration of WP1066 in the brain 
tissue was below 2 µM (Fig. 1E), we next wanted to rule 
out the possibility that the inhibitory effect of WP1066 
against brain metastasis was caused by cytotoxicity-
induced apoptosis using a TUNEL assay. The number of 
TUNEL-positive cells in the tumor sections was almost 
same in vehicle-treated mice and WP1066-treated mice 
(Supplemental Fig. S3), suggesting that WP1066 did 
not induce apoptosis of tumor cells. Thus, the inhibitory 
effect of WP1066 on brain metastasis was not due to 
cytotoxicity.
WP1066 reduced MMP9 expression and invasion 
of brain metastatic cells
We sought to determine the effects of WP1066 on 
invasion ability of brain metastatic breast cancer cells. 
WP1066 (1 µM) led to a significant decrease of invasion 
ability of both MDA-MB-231BR and BT-474BR cells 
(Fig. 2B). Next, because tumor invasion is through 
degradation extracellular matrix and basement membrane 
by matrix metalloproteinases, we assessed the changes 
of MMP-9, the main matrix metalloproteinases in the 
above cell lines. MMP9 protein level and activity were 
decreased by 1 µM WP1066 in both cell lines (Fig. 2C-F). 
Consistent with the in vitro results, the level of MMP9 
was significantly lower in brain metastases of MDA-MB-
231BR cells from WP1066-treated mice than in brain 
metastases from control mice (Supplemental Fig. S4).
WP1066 reduced VEGF expression and 
angiogenic potential of brain metastatic cells
Since angiogenesis is another major step of 
metastasis, we examined whether WP1066 would 
affect angiogenesis of brain metastases by assessing 
vascularization of brain metastases of MDA-MB-231BR 
cells. Brain metastases in the control group were highly 
vascularized whereas brain metastases in the WP1066 
treatment groups had lower microvessel density (Fig. 3A 
and B).
Therefore, we determined the effects of WP1066 
on the angiogenic ability of brain metastatic cells by 
conducting an endothelial cell tube formation assay with 
mouse brain endothelial cell line bEnd.3. The conditioned 
medium from WP1066-treated MDA-MB-231BR 
cells significantly reduced capillary tube formation, as 
compared with the conditioned medium from control 
cells (Fig. 3C). Moreover, WP1066 (1 µM) significantly 
reduced the expression of VEGF in MDA-MB-231BR 
and BT-474BR cells (Fig. 3D). Consistently, in the brain 
metastases, VEGF expression was prominent in the MDA-
MB-231BR control group but was significantly decreased 
in WP1066 treatment groups (Supplemental Fig. S4).
VEGF induced VEGFr2 expression in brain 
endothelial cells through stat3 activation
The above data suggested that VEGF in the 
conditioned medium of brain metastatic cells might 
activate brain endothelial cells and cause them to undergo 
angiogenesis. Therefore, we examined the VEGFR2 
phosphorylation in bEnd.3 cells cultured with conditioned 
medium of brain metastatic cells, since pVEGFR2 
is a marker for endothelial cell activation [32]. The 
conditioned medium of MDA-MB-231BR cells induced 
up-regulation of pVEGFR2, as compared with serum-
free culture medium (Fig. 4A). Knockdown of VEGFR2 
impaired the angiogenic ability of bEnd.3 cells induced by 
the conditioned medium (Fig. 4A and B), indicating that 
VEGFR2 is indeed a marker for endothelial cell activation.
Next, we tested whether VEGF in the conditioned 
medium is the factor that caused VEGFR2 activation. 
Exogenous human VEGF increased the level of pVEGFR2 
in bEnd.3 cells in serum-free medium (Fig. 4C). In 
contrast, a VEGF neutralizing antibody decreased the 
level of pVEGFR2 in bEnd.3 cells in conditioned medium 
(Fig. 4C). Moreover, the levels of pStat3 changed in 
parallel with the changes of pVEGFR2 (Fig. 4C), which is 
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Figure 2: Effects of WP1066 on MDA-Mb-231br and bt-474br cells. (A) Cytotoxicity of WP1066 was measured by MTT 
assay. Cells were treated with DMSO or with the indicated concentrations of WP1066 for 72 hours. Values are means ± SD for triplicate 
experiments. **, P<0.05; ***, P<0.001. (B) Cells were treated with DMSO or WP1066 (1 μM). Then, invasiveness was determined 16 
hours (MDA-MB-231BR cells) or 24 hours (BT-474BR cells) after treatment. Left panels, representative photos of the results. Right panels, 
quantification of the results. Each column indicates the mean ± SD from results of three different experiments. ***, P<0.001. (C, D) MMP9 
and β-actin protein expression following treatment with 1 μM WP1066 analyzed by immunoblotting. (E, F) MMP9 activity in the culture 
media of cells treated with DMSO or WP1066 1 μM determined by gelatin zymography analysis. The MMP9 intensity was quantified by 
using Quantity One software from BIO-RAD. Control were given as 1.00.
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Figure 3: WP1066 inhibited angiogenesis of MDA-Mb-231br-cell in vivo and in vitro. (A) CD31-positive blood vessels in 
brain sections from MDA-MB-231BR-cell-injected mice in the vehicle, early WP1066 treatment, and late WP1066 treatment groups. (B) 
Quantitative analysis of CD31-positive blood vessels in the brain sections of groups described in (A). Blood vessel density and average 
diameter were analyzed in 10 random 0.25-μm2 fields of each section. (C) bEnd.3 cells were treated with conditioned medium (CM) from 
MDA-MB-231BR cells (control), MDA-MB-231BR cells treated with vehicle, or WP1066 1 μM. The bEnd.3 cells then were subjected for 
tube formation assay. Tube formation in each group was photographed (left panel), and right panels show summary data (Mean ± SEM) 
from 3 separate experiments. *, P<0.05. (D) Quantification of VEGF concentrations by ELISA in culture media of MDA-MB-231BR and 
BT-474BR cells treated with DMSO or 1 μM WP1066. Each column indicates the mean ± SEM from results of five different experiments. 
*, P<0.05; ***, P<0.001.
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Figure 4: WP1066 inhibited stat3/VEGFr-2 signaling in brain endothelial cells. (A) bEnd.3 cells were transfected with 100 
nmol/L siControl or siVEGFR-2 for 48 hours in normal medium (serum free) and conditioned medium of MDA-MB-231BR cells. Protein 
expression of VEGFR-2, pVEGFR-2, pStat3, Stat3, and β-actin was analyzed by immunoblotting. (B) bEnd.3 cells were transfected with 
100 nmol/L siControl or siVEGFR-2 for 48 hours and then subjected for tube formation assay with conditioned medium (CM) of MDA-
MB-231BR cells. Lefts panels show representative experiments and right panels show quantification data (mean ± SEM) from three 
separate experiments. **, P<0.01; ***, P<0.001. (C) bEnd.3 cells were pretreated with a recombinant human VEGF or control vehicle 
in normal medium or pretreated with a VEGF neutralizing antibody (VEGF-Ab) or IgG in CM of MDA-MB-231BR cells. Then protein 
expression of pVEGFR-2, VEGFR-2, pStat3, Stat3, and β-actin in the cells was analyzed by immunoblotting. Right panels, quantification 
of pStat3 and pVEGFR-2 immunoblotting results. Each column indicates the mean ± SD from results of three different experiments. **, 
P<0.01; ***, P<0.001. (D) bEnd.3 cells were treated with 1 μM WP1066 in CM of MDA-MB-231BR cells for 24 hours, and whole-cell 
lysates were subjected to western blotting for pStat3, Stat3, VEGFR-1, VEGFR-2, and β-actin (left panel). Right panels, quantification 
of pStat3 and VEGFR-2 immunoblotting results. Each column indicates the mean ± SD from results of three different experiments. **, 
P<0.01; ***, P<0.001.
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consistent with previous reports of VEGF activating Stat3 
via VEGFR2 phosphorylation [33].
Surprisingly, the level of VEGFR2 was increased in 
bEnd.3 cells in conditioned medium of MDA-MB-231BR 
cells (Fig. 4D). Moreover, the level of VEGFR2, but not 
the level of VEGFR1, was lower in bEnd.3 cells treated 
with WP1066 in the conditioned medium than in bEnd.3 
cells treated with control vehicle in the conditioned 
medium (Fig. 4D). Furthermore, the level of pStat3 was 
lower in in bEnd.3 cells treated with WP1066 in the 
conditioned medium than in bEnd.3 cells treated with 
control vehicle in the conditioned medium (Fig. 4D), but 
the total Stat3 level was not affected by WP1066 treatment 
(Fig. 4D). These results suggested that VEGFR2 increase 
induced by conditioned medium of MDA-MB-231BR 
cells was due to the activation of Stat3.
stat3 directly regulated the transcription of 
VEGFr2
We tested whether VEGFR2 is a downstream 
transcriptional target of Stat3. Knockdown of Stat3 in 
bEnd.3 cells in serum-free medium decreased VEGFR2 
expression whereas transfection of a constitutively 
activated mutant of Stat3 (Stat3C) plasmid led to increased 
VEGFR2 expression in bEnd.3 cells (Fig. 5A), indicating 
that Stat3 regulates the basal levels of VEGFR2 in the 
cells. Furthermore, knockdown of Stat3 expression in 
bEnd.3 cells in conditioned medium decreased VEGFR2 
expression (Fig. 5A). 
Next, we analyzed the sequence of the murine 
VEGFR-2 promoter by using the Stat3 consensus 
sequences AA (N4) TT and AA (N5) TT [34]. We 
identified two putative Stat3-binding sites in the VEGFR-2 
promoter (Fig. 5B). Both of the Stat3-binding regions of 
the VEGFR-2 promoter bound to endogenous Stat3 protein 
in bEnd.3 cells by ChIP assays (Fig. 5C). Moreover, we 
examined whether Stat3 activation transactivates the 
VEGFR-2 promoter by using a murine VEGFR-2 (flk1) 
promoter luciferase reporter [35]. Overexpressed Stat3C 
upregulated VEGFR-2 promoter activity in bEnd.3 cells 
cultured in serum-free medium (Fig. 5D). Furthermore, 
VEGFR2 promoter activity was increased in bEnd.3 cells 
in conditioned medium of MDA-MB-231BR cells (Fig. 
5D), whereas VEGFR2 promoter activity was decreased 
in bEnd.3 cells with Stat3 siRNA or with conditioned 
medium of MDA-MB-231BR cells treated with WP1066 
(Fig. 5D). Consistent with the in vitro results, VEGFR-2 
expression in brain metastases was significantly reduced 
by WP1066 treatment in mice (Supplemental Fig. S4). 
Collectively, these results indicated that VEGFR2 is a 
direct transcriptional target of Stat3 and that WP1066 
downregulates VEGFR-2 expression by inhibition of 
Stat3.
WP1066 inhibited the activation hence migration 
and invasion of brain endothelial cells induced by 
brain metastatic breast cancer cells
The above results indicated that Stat3 activity 
regulated VEGFR-2 in brain endothelial cells and hence 
regulated their activation, thus, we examined whether 
WP1066 has direct cytotoxic effects on brain endothelial 
cells. WP1066 at low concentrations (1-3 µM) was not 
cytotoxic to bEnd.3 cells (Fig. 6A). However, a low 
concentration of WP1066 (1 µM) inhibited the activation 
of brain endothelial cells induced by brain metastatic 
breast cancer cells (Fig. 6B).
Since migration and invasion of brain endothelial 
cells require the activation of the cells, we examined 
whether conditioned medium of MDA-MB-231BR 
cells could induce migration and invasion of brain 
endothelial cells. Migration and invasion of bEnd.3 cells 
in conditioned medium of MDA-MB-231BR cells was 
increased compared to that in serum-free medium (Fig. 
6C and D). In contrast, migration and invasion of bEnd.3 
cells in conditioned medium from WP1066-treated MDA-
MB-231BR cells was decreased (Fig. 6C and D). These 
results indicated that WP1066 inhibited the invasion and 
migration of brain endothelial cells induced by brain 
metastatic breast cancer cells.
DIscUssION
In the present study, we sought to determine 
the role of Stat3 in the interaction between tumor cells 
and endothelial cells in breast cancer brain metastases. 
Our novel clinical and mechanistic evidence strongly 
suggests that activated Stat3 binds directly to the 
VEGFR2 promoter and increases its transcription (Fig 
6E). Conversely, VEGFR2 positively regulates activation 
of Stat3 and invasion of brain endothelial cells (Fig 6E). 
Moreover, suppression of Stat3 activation by the small 
molecular inhibitor WP1066 inhibited the activation 
of brain endothelial cells and brain metastasis of breast 
cancer cells in an animal model, presumably by inhibition 
of the transcription of Stat3-target genes including 
VEGFR2 and MMP-9 in both endothelial cells and tumor 
cells (Fig 6E).
The growth and propagation of brain metastases 
depend on the establishment of an adequate blood 
supply—i.e., angiogenesis. The angiogenic phenotype of 
brain metastases have been shown to be associated with 
an increase in the production of proangiogenic molecules 
by the tumor cells and brain environments [2-5]. Previous 
studies have established that VEGF is involved in breast 
cancer brain metastasis [36]. However, the function of 
VEGF depends on the activation of receptors, including 
VEGFR2.
VEGFR2 is mainly expressed in endothelial cells 
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Figure 5: stat3 signaling regulates VEGFr-2 expression in bEnd.3 cells. (A) bEnd.3 cells were transfected with 100 nmol/L of 
siRNA (siControl or siStat3) or 6 μg of cDNA plasmid (vector or Stat3C) for 48 hours with serum-free normal medium (NM) or conditioned 
medium of MDA-MB-231BR cells (CM). Protein expression of Stat3, VEGFR-2, and β-actin was analyzed by immunoblotting. (B) 
Schematic structure of the murine VEGFR2 promoter with the sequences of Stat3-binding sites. (C) ChIP assays in bEnd.3 cells cultured 
with CM of MDA-MB-231BR cells. Chromatin fragments of the cells were immunoprecipitated with Stat3 antibody or IgG and subjected 
to PCR using primers for both Stat3-binding sites. (D) Stat3 transactivates VEGFR-2 promoter. Left, bEnd.3 cells were transfected with the 
murine VEGFR2 promoter and Stat3C or control vector (6 μg) for 48 hours in NM. Luciferase activities of the cells were then determined. 
Right, bEnd.3 cells were transfected with the murine VEGFR2 promoter and siStat3 or siControl (100 nmol/L) for 48 hours in CM of MDA-
MB-231BR cells or treated with WP1066. bEnd.3 cells transfected with the murine VEGFR2 promoter in serum-free normal medium (NM) 
served as a control. Luciferase activities of the cells were then determined.
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Figure 6: WP1066 inhibits the invasion and migration ability of bEnd.3 cells. (A) Cytotoxicity of WP1066 in bEnd.3 cells 
by MTT assay. bEnd.3 cells were treated with various concentrations of WP1066 or with DMSO for 72 hours. Values are means ± SD for 
triplicate experiments. *, P<0.1; #, P<0.001. (B) bEnd.3 cells were treated with vehicle or WP1066 1 μM in CM of MDA-MB-231BR cells. 
Protein expression of VEGFR-2, pVEGFR-2, and β-actin was analyzed by immunoblotting. (C) bEnd.3 cells were cultured with serum-
free medium or CM from MDA-MB-231BR cells treated with vehicle or WP1066 1 μM. Then migration ability was determined using the 
migration assay at 12 hours. Left panels, representative photos of the results. Right panel, quantification of results. Each column indicates 
the mean ± SD from results of three different experiments. **, P<0.01; ***, P<0.001. (D) bEnd.3 cells were cultured medium as described 
in (C). Then invasiveness was determined using the invasion assay at 16 hours. Left panels, representative photos of the results. Right 
panel, quantification of results. Each column indicates the mean ± SD from results of three different experiments. **, P<0.01; ***, P<0.001. 
(E) Stat3 regulates breast cancer cell brain metastasis by affecting interaction between tumor cells and endothelial cells and tumor cell 
invasive. Activated Stat3 in tumor cells upregulates the expression of VEGF that induces the phosphorylation of VEGFR2 in endothelial 
cells. The phosphorylated VEGFR2 leads to phosphorylation hence activation of Stat3 in endothelial cells. Then the activated Stat3 directly 
upregulates VEGFR2 expression in endothelial cells, which leads to further activation of VEGFR2 in the cells, increasing their infiltration 
and angiogenesis. Therefore, Stat3 activation orchestrates the interaction between endothelial and tumor cells. Stat3 also directly regulates 
MMP-9 expression hence breast cancer cell and endothelial invasion. WP1066 can effectively inhibit tumor angiogenesis and invasion thus 
brain metastasis mediated by Stat3.
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[11]. VEGFR2 activation induces cell proliferation, 
migration, and tube formation of endothelial cells [37]. 
VEGFR2 is also expressed in brain metastasis-associated 
endothelial cells [38]. Targeting VEGFR2 with an 
anti-VEGFR2 antibody in combination with a HER2 
inhibitor significantly slowed breast cancer growth in 
the brain, resulting in a striking survival benefit [38]. 
Furthermore, we found that MDA-MB-231BR cells also 
express VEGFR2 (data not shown). Therefore, VEGFR2 
appears to be a critical target for the suppression of 
brain metastasis. However, the mechanisms for the 
overexpression and activation of VEGFR2 in breast cancer 
brain metastasis are unclear.
The transcription factors Sp1, HoxB5, and GATA-
2 have been implicated in regulation of VEGFR2 
expression via its promoter in other diseases [39-
41] whereas the transcription factor FoxC2 regulates 
VEGFR2 expression through binding of VEGFR-2 
enhancer [14]. The current study is the first to show that 
Stat3 regulates the transcription of VEGFR2. Our data 
adds a new mechanism to the body of knowledge on 
the transcriptional regulation of VEGFR2 expression by 
providing evidence that VEGFR2 is a direct transcriptional 
target of Stat3 and that Stat3 critically controls constitutive 
and inducible VEGFR2 expression in endothelial cells. 
More importantly, our study indicates that Stat3 activation 
orchestrates the interaction between endothelial cells 
and tumor cells, which is known to be crucial for tumor 
growth and metastasis [6, 42-45]. Stat3 upregulates VEGF 
expression in tumor cells and that VEGF induces the 
activation of VEGFR2 in endothelial cells. The activated 
VEGFR2 then activates Stat3 in endothelial cells, which 
leads to VEGFR2 upregulation and further activation. 
This Stat3-orchestrated interaction between endothelial 
and tumor cells resulted in a number of cellular activities 
involved in angiogenesis, including endothelial cell 
migration, invasion and tube formation. Blocking of Stat3 
by WP1066 resulted in reduced VEGFR-induced signaling 
and angiogenesis, which further supports the role of Stat3 
in the interaction of tumor cells and endothelial cells. 
Our data validate, in a preclinical model, the 
efficacy of WP1066 for the inhibition of brain metastasis 
by human breast cancer cells. The inhibition of brain 
metastasis by WP1066 was paralleled by reduced pStat3 
staining in the remaining lesions in vivo, confirming that 
the drug affected its intended target. Taken together, our 
findings indicate that blocking Stat3 activity with WP1066 
may have promise in the treatment of brain metastasis 
of breast cancer through targeting both tumor cells and 
tumor-associated endothelial cells.
MAtErIALs AND MEtHODs
cell lines and culture conditions
MDA-MB-231BR and BT-474BR “brain-seeking” 
cell lines were described previously [26, 28]. Mouse brain 
endothelial cell line bEnd.3 was purchased from American 
Type Culture Collection. All cell lines were maintained in 
Eagle’s MEM supplemented with 10% fetal bovine serum, 
sodium pyruvate, nonessential amino acids, L-glutamine, 
and a twofold vitamin solution (Flow Laboratories).
Human tissue specimens
Tissue from human breast invasive ductal carcinoma 
and breast cancer brain metastases were coded without any 
patient identifiers. The use of the tissue was approved by 
the Institutional Review Board of The University of Texas 
MD Anderson Cancer Center. Archival paraffin-embedded 
specimens from 90 invasive ductal carcinomas and 89 
breast cancer brain metastases were used in the study.
reagents
WP1066 was synthesized at The University of Texas 
MD Anderson Cancer Center and dissolved in dimethyl 
sulfoxide (DMSO) for in vitro studies. For in vivo 
experiments, WP1066 was administered via intraperitoneal 
injection in a vehicle of DMSO/polyethylene glycol (PEG) 
300 (1:4 ratio) (Sigma). Recombinant human VEGF and 
neutralizing VEGF antibody were from R&D Systems. 
SMARTpool siRNA duplexes specific for Stat3 and 
VEGFR2 and a nontargeting siRNA (siControl) were 
purchased from Dharmacon.
Experimental brain metastasis model
Female athymic BALB/c nude mice were purchased 
from the National Cancer Institute (Frederick, MD). The 
mouse experiments were conducted under a protocol 
approved by the Institute Animal Care and Use Committee 
of MD Anderson Cancer Center. Mice were inoculated 
with 5 x 105 MDA-MB-231BR cells in the heart’s left 
ventricle. A 100-μL intraperitoneal injection of WP1066 
(40 mg/kg in DMSO/PEG 300 vehicle) or vehicle alone 
was administrated every other day. The Size of metastases 
was measured by 16mm2 ocular grid. The mean numbers 
of large metastases (>300 μM on the long axis) and 
micrometastases (smaller than large metastases) were 
determined by counting the number of metastases from 
one hemisphere of the brain as described previously [4]. 
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Preparation of tumor cell conditioned medium
MDA-MB-231BR or BT-474BR (5x106) were 
seeded in 10cm plates and incubated overnight at 37oC. 
The cells were washed twice with Hanks’ balanced salt 
solution and cultured for an additional 24 h in serum-
free medium, and the supernatants were collected as 
conditional medium. Also, MDA-MB-231BR or BT-
474BR cells were treated with DMSO or WP1066 (1 
µM) in serum-free culture medium for 24 hours, and the 
supernatants were collected as conditional medium.
Western blot analysis
Standard western blotting of whole cell lysates was 
performed with antibodies for Stat3, Stat3 phosphorylated 
at Tyr705 (Cell Signaling Technologies), VEGF, VEGFR2, 
and phosphorylated VEGFR2 (Santa Cruz Biotechnology). 
β-actin (Sigma) was used as a control for loading. 
statistical analysis
The significance of the data from patient specimens 
was determined by χ2 test. The significance of the in 
vitro data was determined by Student’s t-test (two-
tailed), whereas the significance of the in vivo data was 
determined by using one-way analysis of variance.
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